Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02448043 · ClinicalTrials.gov registry record · NA
Cutaneous Prostaglandin Application: Nail Growth, Nail Brittleness, and Eye Pressure
A NA study of Intraocular Pressure and Nail Growth Cessation, sponsored by Northwestern University.
- Completed
- Registry status
- NA
- Development phase
- 45
- Enrollment target
- 1
- Study location
NCT02448043: Completed NA study of Intraocular Pressure and Nail Growth Cessation, sponsored by Northwestern University.
NCT02448043 is a NA study of Intraocular Pressure and Nail Growth Cessation that has completed, run by Northwestern University. The registered enrollment target is 45 participants, below the 83-participant average among 9 other Intraocular Pressure trials with a reported enrollment target (46% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02448043, a NA study of Intraocular Pressure and Nail Growth Cessation, has completed, sponsored by Northwestern University.
- COMPLETED
- Registry status
- NA
- Development phase
- 45 participants
- Enrollment target
- 1
- Study location
Study Summary
Topical prostaglandin agents are used to help reduce eye pressure in glaucoma patients. Bimatoprost (Lumigan 0.01%) is such an agent (Allergan, Inc.). Several of our patients on bimatoprost and an observational study of patients on bimatoprost in another center reported that fingernails grew longer and became less brittle using the topical eye drops to the eyes. The purpose of the double-blinded study is to determine whether the application of the eye drops directly to the proximal nail fold of one hand using the opposite hand as a control will result in longer nails, less brittle nails, and reduced eye pressures should any of the medication be absorbed into the systemic circulation.
Primary Outcome
Measured by digital calipers (Ironton 6 in. Stainless Steel Digital Fractional Caliper, Northern Tool and Equipment, Burnsville, MN, USA)
Conditions Studied
Interventions
- DRUG Bimatoprost 0.01%
- OTHER Placebo: saline
Study Locations (1)
Illinois
- David J. Palmer, MD - Glenview
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2015-06-04 |
| Est. Completion | 2016-05-06 |
| Phase | NA |
What the finished NCT02448043 record still lists
NCT02448043 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 83-participant average among 9 other Intraocular Pressure trials with a reported enrollment target (46% lower).
The record links to 2 conditions, with Intraocular Pressure appearing as the primary indexed condition, and to 2 interventions - of which Bimatoprost 0.01% is the first listed.
NCT02448043 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT02448043 about?
NCT02448043 is a clinical study titled "Cutaneous Prostaglandin Application: Nail Growth, Nail Brittleness, and Eye Pressure". Topical prostaglandin agents are used to help reduce eye pressure in glaucoma patients. Bimatoprost (Lumigan 0.01%) is such an agent (Allergan, Inc.). Several of our patients on bimatoprost and an observational study of patients on bimatoprost in another center reported that fingernails grew longer ...
What is the current status of trial NCT02448043?
This trial is currently completed. It is a NA study. The enrollment target is 45 participants. The study started on 2015-06-04. Estimated completion is 2016-05-06.
What conditions does trial NCT02448043 study?
This clinical trial studies the following conditions: Intraocular Pressure, Nail Growth Cessation.
What interventions are being tested in trial NCT02448043?
The interventions under investigation include: Bimatoprost 0.01% (DRUG), Placebo: saline (OTHER).
Who is sponsoring clinical trial NCT02448043?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02448043 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Intraocular Pressure
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02448043's enrollment target sits among peer trials
45 6th of 9 higher than 4 of 9 other Intraocular Pressure trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Intraocular Pressure trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Effect of Raised End-Tidal pCo2 on Choroidal Volume
RECRUITING · NA
-
IOP Elevation Study
RECRUITING · NA
-
Horizontal vs. Vertical Positioning of the iCare Rebound Tonometer and Effects on Intraocular Pressure Readings
COMPLETED · NA
-
Effect of Position and Anesthetic Choice in Intraocular Pressure in Robotic GYN (Gynecologic) Oncology Patients
RECRUITING · Phase 4
-
24-hour Wear Performance and Safety Study of Smartlens miLens Contact Lens for IOP Monitoring
RECRUITING
-
Anterior Segment Optical Coherence Tomography Microstent Positioning
ACTIVE NOT RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI